Prognostic and Predictive Significance of Body Mass Index in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Retrospective Multicenter Cohort Study
Journal of Clinical Medicine · 19.05.2026 · 15 (10) · 3900
DOI: 10.3390/jcm15103900 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.05.2026. Verfasst von Pervin Can Şancı und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Bakircay University Cigli Training and Research Hospital, Izmir 35620, Turkey. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Gastric cancer remains a leading cause of cancer-related mortality worldwide, with a significant number of patients diagnosed at locally advanced stages. While perioperative chemotherapy and surgical resection are the standard treatments, patient outcomes remain heterogeneous. This study aimed to investigate the prognostic and predictive effects of Body Mass Index (BMI) on pathological response, progression-free survival (PFS), and overall survival (OS) in patients receiving neoadjuvant chemotherapy.
Methods
This retrospective, observational cohort study included 192 patients with locally advanced gastric cancer who underwent curative gastrectomy and neoadjuvant chemotherapy between 2018 and 2023. Patients were categorized based on an optimal BMI cutoff value of 24.9 kg/m2.
Results
Patients with a BMI ≥ 24.9 kg/m2 demonstrated a 41% lower 5-year mortality risk compared to those with a lower BMI (HR = 0.59; 95% CI: 0.35–0.99; p = 0.044). The high BMI group had a significantly longer average PFS (54.1 months) compared to the low BMI group (41.4 months). High BMI was associated with a significantly reduced risk of progression (HR: 0.61; 95%CI: 0.38–0.97; p = 0.038. Log-linear regression confirmed that the complete response rate was 73.7% lower in patients with low BMI.
Conclusions
BMI threshold of ≥24.9 kg/m2 is associated with improved pathological response and long-term survival in patients with locally advanced gastric cancer receiving neoadjuvant chemotherapy. These findings suggest that BMI potentially reflects the impact of nutritional status on treatment tolerability and oncological outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Bakircay University Cigli Training and Research Hospital, Izmir 35620, Turkey.
- Department of Oncology, Gaziantep City Hospital, Gaziantep 27470, Turkey.
- Department of Oncology, Kocaeli City Hospital, Kocaeli 41060, Turkey.
- Department of Oncology, Kocaeli University, Kocaeli 41380, Turkey.
ORCID-Profile: Yasemin Bakkal Temi, Umut Kefeli
Zitieren
APA
Can Şancı, P., Seyyar, M., Karakayali, A., Akyol, M., Temi, Y. B., Çabuk, D., Uygun, K., & Kefeli, U. (2026). Prognostic and Predictive Significance of Body Mass Index in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Retrospective Multicenter Cohort Study. Journal of Clinical Medicine, 15(10), 3900. https://doi.org/10.3390/jcm15103900
Vancouver
Can Şancı P, Seyyar M, Karakayali A, Akyol M, Temi YB, Çabuk D, et al. Prognostic and Predictive Significance of Body Mass Index in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Retrospective Multicenter Cohort Study. Journal of Clinical Medicine. 2026;15(10):3900. doi:10.3390/jcm15103900
BibTeX
@article{Cananc2026,
author = {Can Şancı, Pervin and Seyyar, Mustafa and Karakayali, Anil and Akyol, Murat and Temi, Yasemin Bakkal and Çabuk, Devrim and Uygun, Kazım and Kefeli, Umut},
title = {Prognostic and Predictive Significance of Body Mass Index in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Retrospective Multicenter Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {10},
pages = {3900},
doi = {10.3390/jcm15103900}
}
EUVIMED